AMRX
Amneal Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$4.31B
5Y Perf.+181.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
AMRX vs VTRS
Revenue, margins, valuation, and 5-year total return — side by side.
VTRS
Viatris Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$20.25B
5Y Perf.+1.9%
AMRX vs VTRS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AMRX | VTRS |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $4.31B | $20.25B |
| Revenue (TTM) | $3.02B | $14.56B |
| Net Income (TTM) | $72M | $-296M |
| Gross Margin | 36.9% | 34.4% |
| Operating Margin | -0.2% | 1.0% |
| Forward P/E | 13.8x | 7.1x |
| Total Debt | $124M | $14.70B |
| Cash & Equiv. | $282M | $1.35B |
AMRX vs VTRS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AMRX
VTRS
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Amneal Pharmaceutic… (AMRX) | 100 | 281.7 | +181.7% |
| Viatris Inc. (VTRS) | 100 | 101.9 | +1.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AMRX vs VTRS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: VTRS leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Amneal Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
AMRX
Amneal Pharmaceuticals, Inc.
The Income Pick
AMRX is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.17
- Rev growth 8.0%, EPS growth 157.9%, 3Y rev CAGR 10.9%
- Lower volatility, beta 1.17, Low D/E 12.8%, current ratio 2.17x
Best for: income & stability and growth exposure
VTRS
Viatris Inc.
The Long-Run Compounder
VTRS carries the broadest edge in this set and is the clearest fit for long-term compounding and defensive.
- -51.5% 10Y total return vs AMRX's -54.9%
- Beta 0.99, yield 2.8%, current ratio 1.30x
- Lower P/E (7.1x vs 13.8x)
Best for: long-term compounding and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AMRX | 8.0% revenue growth vs VTRS's -3.0% |
| Value | VTRS | Lower P/E (7.1x vs 13.8x) |
| Quality / Margins | AMRX | 2.4% margin vs VTRS's -2.0% |
| Stability / Safety | VTRS | Beta 0.99 vs AMRX's 1.17 |
| Dividends | VTRS | 2.8% yield; the other pay no meaningful dividend |
| Momentum (1Y) | VTRS | +107.8% vs AMRX's +90.0% |
| Efficiency (ROA) | AMRX | 2.0% ROA vs VTRS's -0.8%, ROIC -0.2% vs -6.6% |
AMRX vs VTRS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
AMRX vs VTRS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAMRXLAGGINGVTRS
VTRSViatris Inc.
2leads
AMRXAmneal Pharmaceutical…
2leads
6 Total Categories
CATEGORYLEADERvs VTRSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AMRX4/6
Valuation MetricsMultiples, price ratios, and targets
VTRS5/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
AMRX9/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
VTRS2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AMRX leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
VTRS is the larger business by revenue, generating $14.6B annually — 4.8x AMRX's $3.0B. Profitability is closely matched — net margins range from 2.4% (AMRX) to -2.0% (VTRS). On growth, AMRX holds the edge at +11.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | AMRXAmneal Pharmaceut… | VTRSViatris Inc. |
|---|---|---|
| RevenueTrailing 12 months | $3.0B | $14.6B |
| EBITDAEarnings before interest/tax | $169M | $2.3B |
| Net IncomeAfter-tax profit | $72M | -$296M |
| Free Cash FlowCash after capex | $150M | $1.7B |
| Gross MarginGross profit ÷ Revenue | +36.9% | +34.4% |
| Operating MarginEBIT ÷ Revenue | -0.2% | +1.0% |
| Net MarginNet income ÷ Revenue | +2.4% | -2.0% |
| FCF MarginFCF ÷ Revenue | +5.0% | +11.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +11.5% | +8.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.1% | +105.9% |
AMRX leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
VTRS leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
| Metric | AMRXAmneal Pharmaceut… | VTRSViatris Inc. |
|---|---|---|
| Market CapShares × price | $4.3B | $20.2B |
| Enterprise ValueMkt cap + debt − cash | $4.2B | $33.6B |
| Trailing P/EPrice ÷ TTM EPS | 62.36x | -5.80x |
| Forward P/EPrice ÷ next-FY EPS est. | 13.81x | 7.12x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 248.54x |
| Price / SalesMarket cap ÷ Revenue | 1.43x | 1.42x |
| Price / BookPrice ÷ Book value/share | 4.62x | 1.38x |
| Price / FCFMarket cap ÷ FCF | 15.98x | 10.45x |
VTRS leads this category, winning 5 of 5 comparable metrics.
Profitability & Efficiency
AMRX leads this category, winning 9 of 9 comparable metrics.
Profitability & Efficiency
AMRX delivers a 7.5% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-2 for VTRS. AMRX carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to VTRS's 1.00x. On the Piotroski fundamental quality scale (0–9), AMRX scores 8/9 vs VTRS's 4/9, reflecting strong financial health.
| Metric | AMRXAmneal Pharmaceut… | VTRSViatris Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +7.5% | -2.0% |
| ROA (TTM)Return on assets | +2.0% | -0.8% |
| ROICReturn on invested capital | -0.2% | -6.6% |
| ROCEReturn on capital employed | -0.2% | -8.1% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 4 |
| Debt / EquityFinancial leverage | 0.13x | 1.00x |
| Net DebtTotal debt minus cash | -$158M | $13.4B |
| Cash & Equiv.Liquid assets | $282M | $1.3B |
| Total DebtShort + long-term debt | $124M | $14.7B |
| Interest CoverageEBIT ÷ Interest expense | 2.09x | -0.51x |
AMRX leads this category, winning 9 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — AMRX and VTRS each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AMRX five years ago would be worth $26,385 today (with dividends reinvested), compared to $14,034 for VTRS. Over the past 12 months, VTRS leads with a +107.8% total return vs AMRX's +90.0%. The 3-year compound annual growth rate (CAGR) favors AMRX at 89.4% vs VTRS's 24.2% — a key indicator of consistent wealth creation.
| Metric | AMRXAmneal Pharmaceut… | VTRSViatris Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +8.4% | +40.5% |
| 1-Year ReturnPast 12 months | +90.0% | +107.8% |
| 3-Year ReturnCumulative with dividends | +579.2% | +91.8% |
| 5-Year ReturnCumulative with dividends | +163.8% | +40.3% |
| 10-Year ReturnCumulative with dividends | -54.9% | -51.5% |
| CAGR (3Y)Annualised 3-year return | +89.4% | +24.2% |
Evenly matched — AMRX and VTRS each lead in 3 of 6 comparable metrics.
Risk & Volatility
VTRS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
VTRS is the less volatile stock with a 0.99 beta — it tends to amplify market swings less than AMRX's 1.17 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VTRS currently trades 99.7% from its 52-week high vs AMRX's 90.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AMRXAmneal Pharmaceut… | VTRSViatris Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.17x | 0.99x |
| 52-Week HighHighest price in past year | $15.20 | $17.45 |
| 52-Week LowLowest price in past year | $7.02 | $8.19 |
| % of 52W HighCurrent price vs 52-week peak | +90.3% | +99.7% |
| RSI (14)Momentum oscillator 0–100 | 62.7 | 75.7 |
| Avg Volume (50D)Average daily shares traded | 1.7M | 10.6M |
VTRS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates AMRX as "Buy" and VTRS as "Hold". Consensus price targets imply 23.9% upside for AMRX (target: $17) vs -12.3% for VTRS (target: $15). VTRS is the only dividend payer here at 2.76% yield — a key consideration for income-focused portfolios.
| Metric | AMRXAmneal Pharmaceut… | VTRSViatris Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $17.00 | $15.25 |
| # AnalystsCovering analysts | 16 | 12 |
| Dividend YieldAnnual dividend ÷ price | — | +2.8% |
| Dividend StreakConsecutive years of raises | 0 | 0 |
| Dividend / ShareAnnual DPS | — | $0.48 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.5% |
Insufficient data to determine a leader in this category.
Key Takeaway
AMRX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). VTRS leads in 2 (Valuation Metrics, Risk & Volatility). 1 tied.
Best OverallAmneal Pharmaceuticals, Inc. (AMRX)Leads 2 of 6 categories
Loading custom metrics...
AMRX vs VTRS: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is AMRX or VTRS a better buy right now?
For growth investors, Amneal Pharmaceuticals, Inc.
(AMRX) is the stronger pick with 8. 0% revenue growth year-over-year, versus -3. 0% for Viatris Inc. (VTRS). Amneal Pharmaceuticals, Inc. (AMRX) offers the better valuation at 62. 4x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Amneal Pharmaceuticals, Inc. (AMRX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AMRX or VTRS?
On forward P/E, Viatris Inc.
is actually cheaper at 7. 1x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — AMRX or VTRS?
Over the past 5 years, Amneal Pharmaceuticals, Inc.
(AMRX) delivered a total return of +163. 8%, compared to +40. 3% for Viatris Inc. (VTRS). Over 10 years, the gap is even starker: VTRS returned -51. 5% versus AMRX's -54. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AMRX or VTRS?
By beta (market sensitivity over 5 years), Viatris Inc.
(VTRS) is the lower-risk stock at 0. 99β versus Amneal Pharmaceuticals, Inc. 's 1. 17β — meaning AMRX is approximately 18% more volatile than VTRS relative to the S&P 500. On balance sheet safety, Amneal Pharmaceuticals, Inc. (AMRX) carries a lower debt/equity ratio of 13% versus 100% for Viatris Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — AMRX or VTRS?
By revenue growth (latest reported year), Amneal Pharmaceuticals, Inc.
(AMRX) is pulling ahead at 8. 0% versus -3. 0% for Viatris Inc. (VTRS). On earnings-per-share growth, the picture is similar: Amneal Pharmaceuticals, Inc. grew EPS 157. 9% year-over-year, compared to -466. 0% for Viatris Inc.. Over a 3-year CAGR, AMRX leads at 10. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AMRX or VTRS?
Amneal Pharmaceuticals, Inc.
(AMRX) is the more profitable company, earning 2. 4% net margin versus -24. 6% for Viatris Inc. — meaning it keeps 2. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMRX leads at -0. 2% versus -18. 6% for VTRS. At the gross margin level — before operating expenses — AMRX leads at 36. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AMRX or VTRS more undervalued right now?
On forward earnings alone, Viatris Inc.
(VTRS) trades at 7. 1x forward P/E versus 13. 8x for Amneal Pharmaceuticals, Inc. — 6. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AMRX: 23. 9% to $17. 00.
08Which pays a better dividend — AMRX or VTRS?
In this comparison, VTRS (2.
8% yield) pays a dividend. AMRX does not pay a meaningful dividend and should not be held primarily for income.
09Is AMRX or VTRS better for a retirement portfolio?
For long-horizon retirement investors, Viatris Inc.
(VTRS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 99), 2. 8% yield). Both have compounded well over 10 years (VTRS: -51. 5%, AMRX: -54. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AMRX and VTRS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
VTRS pays a dividend while AMRX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(AMRX: 11.5% · VTRS: 8.1%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.